Florent Gevers, Andrei Iancu, Fritz Lanham, Dan McCurdy and Laura Quatela are the five individuals selected for induction this year by the IP Hall of Fame Academy
Apollo Therapeutics is an innovative biotech formed by three UK universities and three major companies, with a promising model for creating and monetising life sciences IP
A UK Supreme Court justice, a former USPTO acting director, a globally-renowned IP scholar, a trailblazing trademark lawyer and a one-time presidential candidate form the class of 2020 Read more
Patent analysis shows that American companies would need to make big plays if they want to catch the Chinese, but it is almost certainly too late already Read more
Vaccine owners may be forced to hand over trade secrets or have their patents cancelled under legislation endorsed by the upper house of the country’s Congress Read more
The leading vaccine innovator has won plaudits for its commitment not to enforce its coronavirus-related IP rights against other mRNA inventors Read more
It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more
It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more
Dr Richard Fagan of University College London Business tells IAM about the process of turning patents for early-stage research into investable assets Read more
With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more
Pandemic has thrown a spanner in the works for large life sciences companies, which have fewer phase three novel drugs than at any point in the last decade Read more
Vaccine owners may be forced to hand over trade secrets or have their patents cancelled under legislation endorsed by the upper house of the country’s Congress Read more
The launch of Centessa is the latest development in a trend that has big implications for the monetisation of unpartnered or deprioritised IP-backed pharma assets Read more
Vaccine owners may be forced to hand over trade secrets or have their patents cancelled under legislation endorsed by the upper house of the country’s Congress Read more
The launch of Centessa is the latest development in a trend that has big implications for the monetisation of unpartnered or deprioritised IP-backed pharma assets Read more
